注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
嘉和生物药业(开曼)控股有限公司是一家主要从事生物制药产品研发的中国公司。该公司专注于开发及商业化肿瘤学及自身免疫性疾病。该公司的主要的药物包括lerociclib(GB491)、coprelotamab(GB221)、geptanolimab(GB226)、GB492、GB242以及GB223。该公司主要于中国市场开展业务。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Nuoqing Yi | 49 | 2019 | Chairman of the Board |
Qingqing Yi | - | - | Chairman |
Feng Guo | 51 | 2020 | CEO & Chairman |
Zhijian Chen | - | 2021 | Chairman of Scientific Advisory Board |
Edwin Fung | 58 | 2020 | Independent Non-Executive Director |
Wen Chen | 55 | 2020 | Independent Non-Executive Director |
John R. Zalcberg | - | 2021 | Member of Scientific Advisory Board |
Leonard B. Saltz | - | 2021 | Member of Scientific Advisory Board |
Tieming Yu | 41 | 2024 | Non-Executive Director |
David J. Kerr | - | 2021 | Member of Scientific Advisory Board |
Honghao Zhou | 85 | 2020 | Independent Non-Executive Director |
Yangxin Fu | - | 2021 | Member of Scientific Advisory Board |
Alex A. Adjei | 68 | 2021 | Member of Scientific Advisory Board |
John F. Seymour | - | 2021 | Member of Scientific Advisory Board |
Dong Lyu | 49 | 2021 | Non Executive Director |
Yi Liu | 34 | 2022 | Non-Executive Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核